Endothelin: an endothelium-derived vasoactive peptide

Area of Science:

• Cardiovascular Physiology
• Endocrinology
• Molecular Biology

Background:

• Endothelin (ET) is a 21-amino acid vasoactive peptide identified as a potent vasoconstrictor, significantly more potent than other known constrictors like angiotensin II.
• Endothelin-1 (ET-1) is produced in endothelial cells, as revealed by cDNA analysis of porcine and human precursors.
• Despite its potent vasoconstrictive properties, ET also exhibits vasodilator effects at lower doses, though the mechanisms remain debated, with prostacyclin and endothelium-derived relaxing factor (EDRF) implicated.

Purpose of the Study:

• To investigate the dual vasoconstrictor and vasodilator properties of endothelin (ET).
• To explore the heterogeneous hemodynamic responses of ET across different species and vascular beds.
• To understand the role of ET in pathological conditions such as tissue ischemia and vasospasm.

Main Methods:

• Sequence analysis of cloned cDNAs for porcine and human endothelin precursors.
• Experimental studies to assess vasoconstrictor and vasodilator effects of ET.
• Hemodynamic analysis across various species and vascular beds.

Main Results:

• Endothelin (ET) is a potent endogenous vasoconstrictor, surpassing angiotensin II, vasopressin, and neuropeptide Y in potency.
• ET exhibits vasodilator properties at lower concentrations, with prostacyclin and EDRF suggested as mediators.
• Significant heterogeneity in ET's regional hemodynamic effects (vasodilation vs. vasoconstriction) was observed, varying by species and vascular bed.

Conclusions:

• Endothelin (ET) plays a critical role in regulating vascular tonus in both healthy and diseased states.
• The balance between ET's vasodilator and vasoconstrictor actions may be crucial in pathologies like tissue ischemia and vasospasm.
• Further research is needed to fully elucidate the mechanisms underlying ET's complex cardiovascular effects.